REG - Aptamer Group PLC - Notice of Interim Results

AptamerAnnouncement

01/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA4196Ra&default-theme=true

RNS Number : 4196R  Aptamer Group PLC  01 March 2023

1 March 2023

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

NOTICE OF INTERIM RESULTS

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, will announce its interim
results for the six months ended 31 December 2022 on 14 March 2023.

 

Aptamer Group's Chief Executive Officer, Arron Tolley, new incoming Chief
Financial Officer, Rob Quinn, and Chief Technical Officer, David Bunka, will
be hosting an in-person meeting and webcast for sell-side analysts at 10.00am
GMT on 14 March 2023. To register your interest in attending, please email
aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com) .

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
 
    +44 (0) 1904 56 7790

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Mark Brady / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy
                      +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer® platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145.0 billion. Optimer binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORNKFBPKBKBOBB